review Open AccessTop 1% cited
The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Oncotarget · 2016 · Vol. 7(48) · pp. 78985–78993
Yuelun Zhang✉(Chinese University of Hong Kong, Shenzhen)Jin-Qiu Yuan(Hong Kong Jockey Club)Kaifeng Wang(Southern Medical University)Xiaohong Fu(Chinese University of Hong Kong, Shenzhen)Xiaoran Han(Chinese University of Hong Kong, Shenzhen)Diane Threapleton(Hong Kong Jockey Club)Zu‐Yao Yang(Hong Kong Jockey Club)Chen Mao(Chinese University of Hong Kong, Shenzhen)Jin-Ling Tang(Chinese University of Hong Kong, Shenzhen)
Abstract
This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.
Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLung Cancer Research StudiesMedicineInternal medicineMeta-analysisAdenocarcinomaLung cancerOncologyEpidermal growth factor receptorMutationCancerGene
MeSH terms
Carcinoma, Non-Small-Cell LungChinaEuropeFemaleHumansLung NeoplasmsMaleMutationRisk FactorsSmokingPrevalenceGenetic Predisposition to DiseaseWhite PeopleAsian PeopleMutation Rate
Citations
768
FWCI
21.78
field-weighted impact
References
53
Percentile
100%
vs. same field & year
Citations per year
Cited by
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Cancers · 2021 · 528 citations
References
Epidermal growth factor receptor mutations in lung cancer
Nature reviews. Cancer · 2007 · 3,115 citations
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
JNCI Journal of the National Cancer Institute · 2005 · 1,568 citations
The National Comprehensive Cancer Network
Cancer · 1998 · 16,869 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
The Lancet Oncology · 2012 · 5,500 citations
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
The Lancet Oncology · 2009 · 4,101 citations
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
JNCI Journal of the National Cancer Institute · 2005 · 2,385 citations
Mutations of the <b> <i>Epidermal Growth Factor Receptor</i> </b> Gene in Lung Cancer
Cancer Research · 2004 · 1,225 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.